Published in Gene Therapy Weekly, July 7th, 2005
Sangamo is developing engineered zinc finger nucleases (ZFNTM) to correct errors in the DNA sequence of disease-causing genes for so-called monogenic diseases or to disrupt genes that facilitate disease.
In a poster presentation and a Scientific Symposium Session podium presentation by Dale Ando, MD, Sangamo's vice president of therapeutic development and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.